Switching Patients with Non-Dialysis Chronic Kidney Disease from Oral Iron to Intravenous Ferric Carboxymaltose: Effects on Erythropoiesis-Stimulating Agent Requirements, Costs, Hemoglobin and Iron Status
<div><p>Background</p><p>Patients with non-dialysis-dependent chronic kidney disease (ND-CKD) often receive an erythropoiesis-stimulating agent (ESA) and oral iron treatment. This study evaluated whether a switch from oral iron to intravenous ferric carboxymaltose can reduce...
Saved in:
| 主要作者: | |
|---|---|
| 其他作者: | |
| 出版: |
2015
|
| 主题: | |
| 标签: |
添加标签
没有标签, 成为第一个标记此记录!
|
成为第一个发表评论!